New low-dose weekly combo aims to tame bone marrow cancers with fewer side effects

NCT ID NCT05184842

First seen Jan 06, 2026 · Last updated Jun 15, 2026 · Updated 35 times

Summary

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can control the disease while causing fewer treatment delays or interruptions. About 91 adults aged 18 and older will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact Phone: •••-•••-••••

  • University of California Davis Health (UC Davis Health)

    RECRUITING

    Sacramento, California, 95817, United States

  • White Plains Hospital

    RECRUITING

    White Plains, New York, 10601, United States

Conditions

Explore the condition pages connected to this study.